Cargando…
Letter to the Editor Re: Ahn DH, Krishna K, Blazer M, et al. “A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis.” Ther Adv Med Oncol https://doi.org/10.1177/1758834016676011
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455879/ https://www.ncbi.nlm.nih.gov/pubmed/28607582 http://dx.doi.org/10.1177/1758834017699772 |
| _version_ | 1783241119510822912 |
|---|---|
| author | Von Hoff, Daniel D Renschler, Markus F |
| author_facet | Von Hoff, Daniel D Renschler, Markus F |
| author_sort | Von Hoff, Daniel D |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5455879 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | SAGE Publications |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-54558792017-06-12 Letter to the Editor Re: Ahn DH, Krishna K, Blazer M, et al. “A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis.” Ther Adv Med Oncol https://doi.org/10.1177/1758834016676011 Von Hoff, Daniel D Renschler, Markus F Ther Adv Med Oncol Letters to the Editor SAGE Publications 2017-04-16 2017-06 /pmc/articles/PMC5455879/ /pubmed/28607582 http://dx.doi.org/10.1177/1758834017699772 Text en © The Author(s), 2017 http://creativecommons.org/licenses/by-nc/3.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
| spellingShingle | Letters to the Editor Von Hoff, Daniel D Renschler, Markus F Letter to the Editor Re: Ahn DH, Krishna K, Blazer M, et al. “A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis.” Ther Adv Med Oncol https://doi.org/10.1177/1758834016676011 |
| title | Letter to the Editor Re: Ahn DH, Krishna K, Blazer M, et al. “A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis.” Ther Adv Med Oncol https://doi.org/10.1177/1758834016676011 |
| title_full | Letter to the Editor Re: Ahn DH, Krishna K, Blazer M, et al. “A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis.” Ther Adv Med Oncol https://doi.org/10.1177/1758834016676011 |
| title_fullStr | Letter to the Editor Re: Ahn DH, Krishna K, Blazer M, et al. “A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis.” Ther Adv Med Oncol https://doi.org/10.1177/1758834016676011 |
| title_full_unstemmed | Letter to the Editor Re: Ahn DH, Krishna K, Blazer M, et al. “A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis.” Ther Adv Med Oncol https://doi.org/10.1177/1758834016676011 |
| title_short | Letter to the Editor Re: Ahn DH, Krishna K, Blazer M, et al. “A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis.” Ther Adv Med Oncol https://doi.org/10.1177/1758834016676011 |
| title_sort | letter to the editor re: ahn dh, krishna k, blazer m, et al. “a modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis.” ther adv med oncol https://doi.org/10.1177/1758834016676011 |
| topic | Letters to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455879/ https://www.ncbi.nlm.nih.gov/pubmed/28607582 http://dx.doi.org/10.1177/1758834017699772 |
| work_keys_str_mv | AT vonhoffdanield lettertotheeditorreahndhkrishnakblazermetalamodifiedregimenofbiweeklygemcitabineandnabpaclitaxelinpatientswithmetastaticpancreaticcancerisbothtolerableandeffectivearetrospectiveanalysistheradvmedoncolhttpsdoiorg1011771758834016676011 AT renschlermarkusf lettertotheeditorreahndhkrishnakblazermetalamodifiedregimenofbiweeklygemcitabineandnabpaclitaxelinpatientswithmetastaticpancreaticcancerisbothtolerableandeffectivearetrospectiveanalysistheradvmedoncolhttpsdoiorg1011771758834016676011 |